The aim of this study is to analyze data from an existing database named SAATH-7 Star, in order to assess the treatment persistence to basal insulin in Type 2 diabetes patients who had been enrolled in the SAATH-7 Star structured patient education program in India.
This retrospective study will involve secondary analysis of already existing data of Indian T2DM patients who were administered subcutaneous injectable solutions of insulin glargine (Lantus® or Toujeo®), as per routine clinical practice and who were enrolled in a structured educational program named SAATH-7 Star. Six-months data for eligible patients, who were enrolled in the SAATH-7 Star Program during the index period of March 2019-August 2019, collected from the SAATH-7 Star database will be analyzed for the defined objectives. The index date is defined as the date of enrollment in SAATH-7 Star program i.e. 1st month, which will also be considered as the 'Baseline'
Study Type
OBSERVATIONAL
Enrollment
47,885
Investigational Site Number :
Chilly-Mazarin, France
Proportion of patients persisting on insulin glargine (Lantus® or Toujeo®) at the end of 6th month
Time frame: Month 6
Proportion of patients persisting on insulin glargine (Lantus® or Toujeo®) at the end of 3rd month
Time frame: Month 3
Proportion of patients persisting on Lantus® at the end of 3rd and 6th months
Time frame: Month 3 and 6
Proportion of patients persisting on Toujeo® at the end of 3rd and 6th months
Time frame: Month 3 and 6
Change in Lantus® dose at the end of 3rd and 6th months
Time frame: Month 3 and 6
Change in Toujeo® dose at the end of 3rd and 6th months
Time frame: Month 3 and 6
Proportion of patients on Lantus® who switched to other therapy at the end of 6th month
Time frame: Month 6
Proportion of patients on Toujeo® who switched to other therapy at the end of 6th month
Time frame: Month 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.